PubMedCrossRef 17. Collomp K, Ahmaidi S, Chatard JC, Audran M, Prefaut Ch: Benefits of caffeine ingestion on sprint performance in trained and untrained swimmers. Eur J Appl Physiol 1992, 64:377–380.CrossRef 18. O’Rourke MP, O’Brien BJ, Knez WL, Paton CD: Caffeine

has a small effect on 5-km running performance of well-trained and recreational runners. J Sci Med Sport 2008, 11:231–233.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions CJW planned the study, assisted with data collection and wrote the bulk of the manuscript. MJS helped with study design, data interpretation and manuscript preparation. MKB helped with study design, performed genotyping and manuscript preparation. DJB helped GDC-0449 solubility dmso with study design and data collection. MM helped with data collection and manuscript preparation. NDL assisted with data collection, study design and manuscript preparation. Both WD and MH performed genotyping and manuscript preparation. All authors read and approved the final manuscript.”
“Introduction Currently, primary malignant brain tumors and brain metastases are still difficult to treat with cytotoxic agents. Even though new chemotherapeutic schedules have improved results of cancer treatment in other parts of the body (e.g., small-cell lung cancer, breast cancer, various leukemias), the efficacy of these new schedules in brain tumors remains poor [1]. In addition

to the blood brain barrier(BBB), resistance mechanisms at the tumor cell level may BMN-673 include the intrinsic chemo-insensitivity of brain tumors. The BBB is a major impediment to the entry Cediranib (AZD2171) of many therapeutic drugs into the brain, and over the last decade, it has become clear that multispecific, xenobiotic transporters play a significant role at the BBB [2]. The major determinants of drug permeability across the BBB have long been thought to be based solely on lipophilicity and molecular weight. Although many anticancer drugs are highly lipophilic and relatively small, the permeation level of those drugs across the BBB is unexpectedly low [3]. This can be partially explained by the expression

of P-glycoprotein (P-gp) [4, 5]. P-glycoprotein (P-gp) is a 170-kDa transmembrane glycoprotein that is encoded by the human multidrug-resistance gene MDR1 and is an important functional component of the BBB [6]. P-glycoprotein is an adenosine triphosphate (ATP)-dependent pump. When the drug enters the cells, ATP hydrolysis provides the energy for active drug transport, enabling the transporter to function against steep concentration gradients. The drug and ATP initially bind to the protein at their respective binding sites, where ATP hydrolyzes to ADP and yields energy for extrusion of the drug [7]. The intracellular drug concentration remains at a low level, leading to tumor cell resistance. There are two AZD1080 clinical trial different views about the exact location of P-gp in the BBB.